Bullish Case: RAPIDe-3 hit its primary and all 11 secondary endpoints, was published in The Lancet, and the deucrictibant IR NDA is under FDA review with a April 23, 2027 PDUFA. A patient survey shows real unmet demand for oral HAE prophylaxis. Calls outtraded puts by 52%, call skew (35–60 strikes) carries elevated IV, and mean reversion around $30 has held. Approval odds plus BioCryst competitive framing ('selloff overdone') argue the $36→$31 pullback is digested.

Bearish Case: 71 insider sales and zero purchases over six months signal distribution near highs. The stock is -14.2% in a month and Helium's own density puts material mass at $20–27.5 versus the market's smoother center — Helium's odds curve declines steadily at low prices. Flat-to-contango IV (~60–69%) is priced for event risk into PDUFA, so even a benign NDA delay or launch-2028 timeline push (per Claude's BioCryst thesis) could compress the stock toward $25–28.

Potential Outcomes:

1. NDA review progresses cleanly (40%): Lancet publication + complete endpoints support approval; drift back to $32–36 into PDUFA.
2. Deucrictibant prophylaxis/commercial overhang, chop $28–33 (25%): No new catalysts until 2027; launch expected ~2028 keeps upside deferred.
3. CRL or regulatory delay (15%): FDA requests more data; gap toward $24–27; long-dated IV spikes.
4. BioCryst/Orladeyo competition narrative gains (12%): Strong BCRX earnings/2027 outlook in early November pressures PHVS to $27–30.
5. Macro/biotech risk-off or insider-driven pressure (8%): Helium's $20–25 tail realized; sub-$27 move.

October 21, 2026